4th Circ. Undoes $1.25M Verdict In Pradaxa Suit

The Fourth Circuit on Wednesday reversed a $1.25 million verdict against Boehringer Ingelheim in a suit over the bleeding risks of its blood thinner Pradaxa, finding that fraud claims brought by...

Already a subscriber? Click here to view full article